EXCRETION OF A TUMOR-ASSOCIATED TRYPSIN-INHIBITOR (TATI) IN URINE OF PATIENTS WITH GYNECOLOGICAL MALIGNANCY
EXCRETION OF A TUMOR-ASSOCIATED TRYPSIN-INHIBITOR (TATI) IN URINE OF PATIENTS WITH GYNECOLOGICAL MALIGNANCY
复制标题
DOI：
10.1002/ijc.2910310606
复制
发表时间：
1983-01-01
影响因子：
6.4
通讯作者：
STENMAN, UH
中科院分区：
文献类型：
--
作者：
HUHTALA, ML;KAHANPAA, K;STENMAN, UH
早期的研究报告发现，在早期羊水中也发现了一种高浓度的肿瘤相关肽。对该多肽N端序列的测定表明，该多肽与胰腺分泌性胰蛋白酶抑制因子密切相关或相同。因此，该肽被称为肿瘤相关胰酶抑制物(TATI)。用放射免疫法测定148例妇科恶性肿瘤患者和98例非恶性妇科疾病患者及40例严重感染或炎症性疾病患者的尿液中TATI浓度。在参考人群中，TATI的尿药浓度中位数为22微克/克肌酐，中心95%的参考区间为7-50微克/克肌酐。53%的妇科癌症患者、63%的活动性疾病患者和26%的临床缓解期患者尿液水平升高。最高尿TATI水平(11,000微克/克肌酐)是参考范围上限的200倍。宫颈癌患者升高的频率最高。在严重的支气管肺部感染和胰腺炎患者中也观察到TATI的排泄增加。尽管TATI排泄增加不是癌症特有的，但TATI升高水平在妇科恶性肿瘤和非恶性疾病之间的区别比大多数其他假定的肿瘤标志物更好，而且活动期疾病患者TATI排泄增加对于了解肿瘤生物学可能是重要的。
Earlier studies reported the finding of a tumor-associated peptide that also occurred at high concentrations in early amniotic fluid. Determination of the N-terminal sequence of this peptide revealed that it is closely related or identical to the pancreatic secretory trypsin inhibitor. Therefore, the peptide is called tumor-associated trypsin inhibitor (TATI). The concentration of TATI was determined by radioimmunoassay in the urine of 148 patients with various forms of gynecologic malignancy and in a reference population consisting of 98 patients with non-malignant gynecologic disease, and also in 40 patients with severe infections or inflammatory disease. In the reference population, the median urinary concentration of TATI was 22 .mu.g/g creatinine and the central 95% reference interval was 7-50 .mu.g/g creatinine. Elevated urinary levels were observed in 53% of all patients with gynecologic cancer, in 63% of those with active disease and 26% of those in clinical remission. The highest urinary TATI level (11,000 .mu.g/g creatinine) was > 200 times the upper limit of the reference range. Patients with cervical cancer had the highest frequency of elevated values. Increased excretion of TATI was also observed in patients with severe bronchopulmonary infections and pancreatitis. Although increased excretion of TATI is not cancer-specific, the distinction by elevated levels of TATI between malignant and nonmalignant gynecologic disease is better than by most other putative tumor markers, and the increased excretion of TATI in patients with active disease can be important for the understanding of tumor biology.